Roche, Breast cancer
Digest more
A new study finds AI can potentially detect artery calcification in routine mammograms, helping identify women at risk of ...
Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It's the most common cancer in women, excluding skin cancers.
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.
Breast cancer mortality has decreased in high-income countries but increased in lower-income ones — a stark divide in outcome in the most common cancer among women worldwide.
Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. The trial included patients with ...
Researchers have shown that a standard mammogram can be capable of uncovering not just breast cancer, but a woman’s risk of heart disease as well, by using artificial intelligence to help | Using AI ...
Valerie Bertinelli is looking back on facing “gross” complications from her breast implants that she says “scared the piss out of me.” In her newly released memoir, “Getting Naked: The Quiet Work of ...
An artificial intelligence (AI) algorithm used to detect breast cancer in screening scans has been adapted into a risk score ...
FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
One woman who took part in research and had breast cancer detected says she feels "incredibly lucky".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results